Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Letters
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-1074 Online ISSN: 1792-1082
Journal Cover
January-2017 Volume 13 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
January-2017 Volume 13 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Anti-tumor and anti-invasion effects of a combination of 4-methylumbelliferone and ionizing radiation in human fibrosarcoma cells

  • Authors:
    • Ryo Saga
    • Satoru Monzen
    • Mitsuru Chiba
    • Hironori Yoshino
    • Toshiya Nakamura
    • Yoichiro Hosokawa
  • View Affiliations / Copyright

    Affiliations: Department of Radiological Life Sciences, Division of Medical Life Sciences, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori 036‑8564, Japan, Department of Biomedical Sciences, Division of Medical Life Sciences, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori 036‑8564, Japan
  • Pages: 410-416
    |
    Published online on: November 15, 2016
       https://doi.org/10.3892/ol.2016.5385
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Hyaluronan (HA) is a major component of the extracellular matrix that is synthesized in excess in cancer tissues. 4‑methylumbelliferone (MU) inhibits the synthesis of HA and is closely related to the invasion and metastasis of cancer. However, the effects of MU in conjunction with cancer radiotherapy remain unknown. The present study assessed the anti‑tumor and anti‑invasion effects of the concomitant use of ionizing radiation (IR) and 100 µM MU on human fibrosarcoma HT1080 cells. Cell viability and cellular invasion potency assays were performed. There was a greater decrease in the viability of cells cultured with a combination of 2 Gy IR and MU compared with untreated control cells. In addition, cell cycle distribution analysis demonstrated that a higher proportion of these cells were in the sub‑G1 phase and higher fractions of annexin‑V positive, propidium iodide positive cells (i.e., apoptotic cells) were observed. HA concentration in the 2 Gy irradiated culture was similar to that in the non‑irradiated control culture, however, it significantly decreased following the administration of both MU alone and 2 Gy IR with MU. Furthermore, treatment with 2 Gy IR and MU resulted in a significant decrease in the invasion rate and matrix metalloproteinase (MMP)‑2 and MPP‑9 expression. Taken together, these results suggest that the administration of MU with 2 Gy IR is effective at reducing HA production, cell invasion and the metastatic potential of cancer cells.

Introduction

External radiotherapy for primary solid tumors is generally effective as it is non-invasive and improves local control in the target region. However, certain dispersal targets in radiotherapy induce poor prognosis, including distant metastasis and radiation resistance, in human fibrosarcoma HT1080 cells (1). Thus, research has focused on the metastasis-inducible factor hyaluronan (HA) to resolve these concerns pertaining to radiotherapy. HA is the primary component of the extracellular matrix and may promote cellular motility by activating the epidermal growth factor receptor through Akt phosphorylation signaling (2). In addition, HA regulates the expression of matrix metalloproteinases (MMP)-2 and −9, which belong to the type IV collagenase family (3). A previous report has clarified that the mutant overexpression of MMP-2 and −9 promotes distant metastasis and invasion (4). An inhibitor of HA synthesis, 4-methylumbelliferone (MU), was identified as a possible countermeasure in prostate, lung and breast cancer cell models (5–7). To the best of our knowledge, there have been no published studies investigating the administration of MU in conjunction with the exposure of cancer cells to ionizing radiation (IR); however, the chemotherapy drugs cisplatin and paclitaxel have been clinically used along with radiotherapy in various solid tumors (8–10).

It was hypothesized that if the mechanism underlying the synergistic anti-tumor effect of IR with MU was clarified, a novel countermeasure to distant metastases may be proposed. Therefore, in the present study, the effect of the administration of MU with IR on cell survival fraction, HA synthesis, and MMP expression was analyzed in HT1080 cells.

Materials and methods

Reagents

MU, an HA inhibitor, was purchased from Nacalai Tesque, Inc., (Kyoto, Japan) and diluted in dimethyl sulfoxide (DMSO; Wako Pure Chemical Industries, Ltd., Osaka, Japan). A Gelatin Zymography kit for detecting MMP was purchased from Cosmo Bio Co., Ltd., (Tokyo, Japan). The Hyaluronan Quantikine® ELISA kit for quantifying HA concentration was purchased from R&D Systems, Inc., (Minneapolis, MN, USA).

Cell culture

Human fibrosarcoma HT1080 cells were purchased from the American Type Culture Collection (Manassas, VA, USA) and cultured in RPMI 1640 medium (Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% heat-inactivated fetal bovine serum (Japan Bio Serum, Fukuyama, Japan) and 1% penicillin/streptomycin (Thermo Fisher Scientific, Inc.) at 37°C in a humidified atmosphere with 5% CO2. The number of viable cells was counted using the trypan blue (Sigma-Aldrich, St. Louis, MO, USA) dye exclusion method. The clonogenic potency of cells was estimated by colony formation assay and appropriate numbers of cells were seeded. Following 8–10 days of incubation, the cell colonies were fixed with methanol, stained with Giemsa (both Wako Pure Chemical Industries, Ltd.) and counted.

Exposure of cells to IR

IR was performed using an X-ray generator (MBR-1520R-3; Hitachi Medical Co. Ltd., Tokyo, Japan) with 0.5 mm aluminum and 0.3 mm copper filters at a distance of 45 cm between the focus and the target. Radiation was carried out at 150 kV, 20 mA, 0.9 Gy/min. During X-ray exposure, the total dose and dose rate were monitored with a thimble ionization chamber placed next to the sample.

Analysis of viable and apoptotic cells

The viability of each cell culture was assessed using an annexin V and propidium iodide (PI) staining kit (BioLegend, Tokyo, Japan). The cell cycle distribution was analyzed by Hoechst 33342 staining. Fluorescence data were collected using the Cell Lab Quanta™ SC MPL Flow Cytometer (Beckman Coulter, Inc., Brea, CA, USA).

Invasion assay

Invasion potential was evaluated using a BioCoat Matrigel invasion chamber (BD Biosciences, San Jose, CA, USA). The HT1080 cell suspension (2.5×104 cells) was added to 24-well chambers and incubated for 22 h at 37°C in a humidified tissue culture incubator at 37°C with 5% CO2. Invasive cells were fixed and stained using a Diff-Quik staining kit (Dade Behring, Inc.; Siemens Healthcare GmbH, Erlangen, Germany). The number of cells in a predetermined field of view (876×659 µm) were counted, allowing a calculation of the invasion rate to be performed using the formula: Invasion rate = (number of invasion cells) / (number of migrated cells) × 100.

HA density quantitation

The Hyaluronan Quantikine® ELISA kit (R&D Systems, Inc.) was used to analyze the HA concentration of the supernatants. At near confluence, 30 µl aliquots of the HT1080 cell culture supernatants were prepared, and 210 µl aliquots of the Calibrator Diluent RD5-18 buffer was added to the kit. The samples were subsequently added and buffer from the kit (HA conjugate and substrate solution) was added to each well. Finally, stop solution was added, and the absorbance of each well was measured at a wavelength of 540 nm using a microplate reader (10043; Bio-Rad Laboratories, Inc., Hercules, CA, USA). HA concentration was calculated from a standard curve of the measured absorbance.

MMP protein and gene expression analysis

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was performed to quantify MMP mRNA expression. Total RNA was extracted from HT1080 cells using an RNeasy® Micro kit (Qiagen, Inc., Valencia, CA, USA) and quantified using a NanoDrop Spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc., Wilmington, DE, USA). First strand cDNAs were synthesized using the iScript™ cDNA Synthesis kit (Bio-Rad Laboratories, Inc.) according to the manufacturer's instructions. The expression of MMP-2, −9 and GAPDH were measured by RT-qPCR using the TaqMan® assay (Applied Biosystems; Thermo Fisher Scientific., Inc.) with Hs01548727_m1 for MMP-2, Hs0095755_m1 for MMP-9, and Hs99999905_m1 for GAPDH. RT-qPCR was performed using the StepOnePlus™ Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific., Inc.) under the conditions of 10 min at 95°C, followed by 40 cycles at 95°C for 15 sec and 60°C for 60 sec. Relative differences in expression were determined by the ΔΔCq method. GAPDH was used as an internal control for each reaction and the mRNA expression of the control was defined as the baseline.

The extracellular protein expression of MMP-2 and −9 were measured using the Gelatin Zymography protease assay kit (Cosmo Bio Co., Ltd.). At near confluence, 70 µl supernatant of serum-free cell culture was mixed with 30 µl sample buffer [8.7% sodium dodecyl sulfate (SDS); 0.5 M Tris-HCl (pH 6.8), 70% glycerol and 0.05% bromophenol blue] and loaded on the gel. Prepared samples were then subjected to electrophoresis on 10% SDS-polyacrylamide gels containing 0.417% gelatin. Following electrophoresis, the gels were washed in 2.5% Triton X-100 for 1 h at room temperature to remove SDS. The gels were subsequently incubated at 37°C for 18 h in a substrate buffer containing 50 mM Tris-HCl (pH 7.5) and 10 mM CaCl2 and stained with 0.25% Coomassie Brilliant Blue R250 in 45% methanol and 10% acetic acid. The section of the substrate degraded by proteases was detected as clear bands. The band sizes were determined by gel densitometry using the program ImageJ ver. 1.44b (National Institutes of Health, Bethesda, MD, USA).

Statistical analysis

The significance of the differences between the control and experimental cultures was determined using the Tukey-Kramer test. Statistical analysis was performed using Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA, USA) with the add-on software Statcel (version 3; OMS Publishing, Inc., Saitama, Japan). P<0.05 was considered to indicate a statistically significant difference. Dose survival curves were fitted using the Boltzmann function.

Results

Cell viability following MU and X-irradiation

MU was dissolved in DMSO prior to being added to the cell culture medium. Cells cultured with 0.1% DMSO were considered controls as the viability of HT1080 and WI38 cells (non-cancer fibroblast cells) with 0.1% DMSO added to the cell culture medium was similar to that of untreated cells. To clarify the toxicity of the MU concentration, HT1080 and WI38 cells were cultured with DMSO containing MU. The survival fraction of HT1080 cells in >100 µM MU decreased significantly (100 µM, 0.3±0.1; 200 µM, 8.0±0.4×10−2) compared to WI38 cells (100 µM, 1.1±0.2; 200 µM, 1.0±0.2; Fig. 1A), indicating that they were more sensitive to MU. The lowest effective concentration, 100 µM MU, was chosen to evaluate the effect of MU with 2 Gy IR due to its specificity for tumor cells.

Figure 1.

Clonogenic potency assay. (A) The toxicity curves of HT1080 and WI38 cells treated with MU (dose, 0–1000 µM) were completed using the colony formation method and the number of colonies were counted 10 days following culture initiation. (B) The surviving fraction of clonogenic cells in HT1080 cells treated with 100 µM MU and/or 2 Gy IR were analyzed. Values are presented as the mean ± standard error of the mean. *P<0.01 vs. control, **P<0.01 vs. 100 µM MU alone. MU, 4-Methylumbelliferone; IR, ionizing radiation.

A clonogenic potency assay was conducted to examine the effect of 100 µM MU with 2 Gy IR on HT1080 cells (Fig. 1B). There was a significantly greater decrease (3.6±0.7×10−1) in the survival of cells treated with 100 µM MU decreased compared with controls (no decrease; Fig. 2B). Furthermore, in cells treated with 100 µM MU and 2 Gy IR, there was a significantly greater decrease (6.4±0.8×10−2) in cell survival compared with cells treated with 2 Gy IR or MU alone. These results indicate that MU with 2 Gy IR is a more effective anti-tumor treatment than 2 Gy IR alone.

Figure 2.

Flow cytometric patterns for the cell cycle. HT1080 cells treated with 100 µM MU and/or 2 Gy IR were cultured for 6 and 24 h. (A) A representative cytogram and quantitative analysis. The percentage of cells in the (B) sub-G1 phase and (C) G2/M phase are presented. Values are presented as mean ± standard error of the mean. *P<0.05 vs. control and **P<0.05 vs. MU without 2 Gy IR. MU, 4-Methylumbelliferone; IR, ionizing radiation.

To clarify whether the decrease in cell survival occurred by cell death and/or quiescence, cell cycle distribution and apoptosis markers were assessed. Following 2 Gy IR and MU treatment, there was a significant increase of the number of cells in the G2/M phase of the cell cycle after 6 h (control, 32.2±0.5%; 2 Gy IR, 37.6±0.9%; 2 Gy IR and MU, 37.3±1.1%) and in the sub-G1 phase after 24 h (control, 0.5±0.1%; 2 Gy IR and MU, 1.0±0.1%; Fig. 2). Furthermore, there was a significant increase of the fraction of annexin-V(+), PI(+) cells, following 2 Gy IR and MU treatment (5.2±0.5%) compared with the control (3.0±0.5%; Fig. 3), indicating increased apoptosis. The results from cells treated with 4 Gy were similar to that of cells treated with 2 Gy (data not shown).

Figure 3.

Analysis of apoptotic cell fraction by concurrent staining with annexin-V and PI. HT1080 cells treated with 100 µM MU and/or 2 Gy IR were cultured for 24 h. (A) A representative cytogram and (B) quantitative analysis of cell fractions are presented. Values are provided as the mean ± standard error of the mean. *P<0.05 vs. control. PI, propidium iodide; MU, 4-Methylumbelliferone; IR, ionizing radiation.

Analysis of cell invasion potential

To verify invasion at a cellular level, the potential invasion rate was quantified. The invasion rate of cells treated with 2 Gy IR and MU was significantly lower (2.3±0.4%) than that of the control (6.0±0.6%; Fig. 4). To evaluate the extracellular environment under 2 Gy IR with 100 µM MU, HA concentrations were analyzed in the culture supernatants. The HA concentration of control HT1080 cells (1.0×105 cells) was 1.5±0.2×102 ng/ml after 24 h and was similar in cells treated with MU or 2 Gy IR alone (MU, 1.3±0.1×102 ng/ml; 2 Gy IR, 1.4±0.1×102 ng/ml; Fig. 5). However, HA concentration following 2 Gy IR treatment with MU was significantly lower (1.1±0.1×102 ng/ml) compared with the control and other treatments (Fig. 5).

Figure 4.

Analysis of cell invasion potency. Invasion rates of HT1080 cells cultured with 100 µM MU and/or 2 Gy IR for 24 h were analyzed using a BioCoat Matrigel invasion chamber. Values are provided as the mean ± standard error of the mean. *P<0.01. MU, 4-Methylumbelliferone; IR, ionizing radiation.

Figure 5.

Quantitative analysis of hyaluronan concentration. The cell culture supernatants of HT1080 cells cultured with 100 µM MU and/or 2 Gy IR for 24 h were collected and quantified by an enzyme-linked immunosorbent assay. Values are presented as the mean ± standard error of the mean. *P<0.01. MU, 4-Methylumbelliferone; IR, ionizing radiation.

Expression of MMPs

The expression of MMP-2 and −9, an indication of cell invasion, were analyzed in cells exposed to 2–4 Gy IR with or without MU. A higher expression of MMP-2 mRNA following 2 and 4 Gy IR was observed compared with the control (Fig. 6A). However, the addition of MU suppressed the expression of MMP-2 mRNA (Fig. 6A). A similar expression of MMP-9 mRNA following treatment with 2 Gy IR and/or MU was observed the control (Fig. 6B). However, the expression of MMP protein in the culture supernatant was strongly suppressed following 2 Gy IR with MU, compared with the control and other treatments (Fig. 6C-E).

Figure 6.

Expression of MMP-2 and −9. (A) MMP-2 and (B) −9 mRNA expression was analyzed using reverse transcription-quantitative polymerase chain reaction in HT1080 cells incubated for 24 h following administration of 100 µM MU and/or 2 or 4 Gy IR. The values presented are the means of 3 separate experiments. The protein expression of MMP-2 and −9, including cell culture supernatants of HT1080 cells cultured with 100 µM MU and/or 2 Gy IR for 24 h, were collected and assayed by gelatin zymography. The bands obtained using (C) electropherogram and quantitative values of typical samples of (D) MMP-2 and (E) MMP-9 are presented. MU, 4-Methylumbelliferone; MMP, matrix metalloproteinase.

Discussion

Previous studies in prostate and breast cancer cells have reported that the anti-tumor effect of MU may be due to the inhibition of cell proliferation and apoptosis induction (5,7). Furthermore, it has been demonstrated that 1.0 mM MU exerts its anti-tumor effect on ovarian cancer by suppressing thymidine phosphorylase expression (11). In another study, Saito et al (12) indicated that MU leads to growth arrest and apoptosis mediated by BAX expression and a reduction in HA synthesis. In the present study, the induction of apoptosis by MU in HT1080 cells was observed, suggesting that the intracellular signaling pathway of apoptosis affected by 100 µM MU and is not dependent on the type of tumor. By contrast, combining 2 Gy IR with MU in fibroblast cells exerted a stronger anti-cell proliferation effect that is specific to cancer without being toxic to normal cells. To the best of our knowledge, this is novel information that has not yet been reported.

It has been demonstrated that IR produces reactive oxygen species (ROS) or free radicals, including X-rays and γ-rays that indirectly and/or directly induce DNA strand breakage and exert various cytotoxic effects (13,14). Braga et al (15) reported previously that HA has antioxidant activity, therefore, it was suggested that the reduction in HA concentration by MU observed in the current study increases the accumulation of oxidative stress and DNA damage by 2 Gy IR.

It is important to control invasion and metastasis when treating cancer, however, this has not yet been achieved. A highly potent invasive tumor exhibits aberrant secretion of HA and overexpression of cluster of differentiation 44 antigen, which acts as the HA receptor (16). HA is produced from injured tissue stroma and is rapidly deposited in the extracellular matrix, where it regulates repair processes through cross-talk with various inflammatory conditions, including carcinogenesis (17). Abnormal secretion of HA has been observed in malignant tumors (18), however, HA is required in normal tissue, therefore, it is important to clarify the regulating system for HA secretion. Kim et al (19) have reported that suppression of MMP-9 activity and vascular endothelial growth factor production in malignant tumor cells reduces tumor metastasis and angiogenic potency. In addition, Rauhala et al (20) have demonstrated that keratinocytes exposed to low-dose UVB radiation increased HA synthesis with the production of ROS. Fibrosarcoma is known as the radioresistant cell (21), which may be related to the induction of HA synthesis by radiation.

Previous studies have demonstrated that gene expression of MMP-2 and −9 is upregulated following IR and is associated with cellular invasion (22). The results of the current study regarding mRNA expression following treatment with 2 Gy and 4 Gy differed in comparison with previous reports. In the current study, the levels of MMP protein significantly decreased following 2 Gy IR with MU (Fig. 6C-E). However, direct comparison of these results may not be possible as the previous reports do not include clear information regarding dose rate and radiation energy.

The regulation of ROS and HA synthesis may be required in fibrosarcoma treatment. The current study presents evidence that a combination of IR with MU is able to inhibit invasion potency and this may be a potential cancer treatment for radioresistant tumors in the case of HA overexpression. Further elucidation and a biological model analysis of the association between radiosensitive tumors and HA synthesis is required in the future.

In conclusion, the present study investigated the effect of combining MU with external radiotherapy as an anti-tumor treatment. Cell viability, extracellular HA concentration and cellular invasion potential in HT1080 cells treated with 2 Gy IR and MU were analyzed. A decrease in HA concentration, invasion rate and expression of MMP-2 and −9 following treatment of 2 Gy IR with MU was observed, along with suppression of clonogenic potential compared with non-treated cells. These results suggest that a combination of 2 Gy IR and MU has a synergic effect as an anti-invasion treatment and significant anti-tumor and -invasion effects in HT1080 cells and thus may be developed for clinical use as an inhibitor of distant metastasis in radiation therapy.

Acknowledgements

The present study was supported by the Japan Society for the Promotion of Science KAKENHI (Tokyo, Japan) Scientific Research and Young Scientist Grants (grant nos. 24591831 and 25861054), and the Hirosaki University Institutional Research Grant (Hirosaki, Japan; grant no. 2014).

References

1 

Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS and Evans HL: Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: An analysis of 1225 patients. Cancer. 97:2530–2543. 2003. View Article : Google Scholar : PubMed/NCBI

2 

Hiraga T, Ito S and Nakamura H: Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res. 73:4112–4122. 2013. View Article : Google Scholar : PubMed/NCBI

3 

Duffy MJ, Maguire TM, Hill A, McDermott E and O'Higgins N: Metalloproteinases: Role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2:252–257. 2000. View Article : Google Scholar : PubMed/NCBI

4 

Toole BP: Hyaluronan-CD44 Interactions in cancer: Paradoxes and possibilities. Clin Cancer Res. 15:7462–7468. 2009. View Article : Google Scholar : PubMed/NCBI

5 

Lokeshwar VB, Lopez LE, Munoz D, Chi A, Shirodkar SP, Lokeshwar SD, Escudero DO, Dhir N and Altman N: Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. Cancer Res. 70:2613–2623. 2010. View Article : Google Scholar : PubMed/NCBI

6 

Arai E, Nishida Y, Wasa J, Urakawa H, Zhuo L, Kimata K, Kozawa E, Futamura N and Ishiguro N: Inhibition of hyaluronan retention by 4-methylumbelliferone suppresses osteosarcoma cells in vitro and lung metastasis in vivo. Br J Cancer. 105:1839–1849. 2011. View Article : Google Scholar : PubMed/NCBI

7 

Urakawa H, Nishida Y, Wasa J, Arai E, Zhuo L, Kimata K, Kozawa E, Futamura N and Ishiguro N: Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo. Int J Cancer. 130:454–466. 2012. View Article : Google Scholar : PubMed/NCBI

8 

Sano D, Matsumoto F, Valdecanas DR, Zhao M, Molkentine DP, Takahashi Y, Hanna EY, Papadimitrakopoulou V, Heymach J, Milas L and Myers JN: Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro. Clin Cancer Res. 17:1815–1827. 2011. View Article : Google Scholar : PubMed/NCBI

9 

Chan AT, Leung SF, Ngan RK, Teo PM, Lau WH, Kwan WH, Hui EP, Yiu HY, Yeo W, Cheung FY, et al: Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 97:536–539. 2005. View Article : Google Scholar : PubMed/NCBI

10 

Byun JW, Lee HS, Song SU, Lee SW, Kim SK, Kim WC, Lee MH and Choi GS: Combined treatment of murine fibrosarcoma with chemotherapy (Paclitaxel), radiotherapy, and intratumoral injection of dendritic cells. Ann Dermatol. 26:53–60. 2014. View Article : Google Scholar : PubMed/NCBI

11 

Tamura R, Yokoyama Y, Yoshida H, Imaizumi T and Mizunuma H: 4-Methylumbelliferone inhibits ovarian cancer growth by suppressing thymidine phosphorylase expression. J Ovarian Res. 7:942014. View Article : Google Scholar : PubMed/NCBI

12 

Saito T, Tamura D, Nakamura T, Makita Y, Ariyama H, Komiyama K, Yoshihara T and Asano R: 4-methylumbelliferone leads to growth arrest and apoptosis in canine mammary tumor cells. Oncol Rep. 29:335–342. 2013.PubMed/NCBI

13 

Bajinskis A, Natarajan AT, Erixon K and Harms-Ringdahl M: DNA double strand breaks induced by the indirect effect of radiation are more efficiently repaired by non-homologous end joining compared to homologous recombination repair. Mutat Res. 756:21–29. 2013. View Article : Google Scholar : PubMed/NCBI

14 

Vignard J, Mirey G and Salles B: Ionizing-radiation induced DNA double-strand breaks: A direct and indirect lighting up. Radiother Oncol. 108:362–369. 2013. View Article : Google Scholar : PubMed/NCBI

15 

Braga PC, Dal Sasso M, Lattuada N, Greco V, Sibilia V, Zucca E, Stucchi L, Ferro E and Ferrucci F: Antioxidant activity of hyaluronic acid investigated by means of chemiluminescence of equine neutrophil bursts and electron paramagnetic resonance spectroscopy. J Vet Pharmacol Ther. 38:48–54. 2015. View Article : Google Scholar : PubMed/NCBI

16 

Kim Y and Kumar S: CD44-mediated adhesion to hyaluronic acid contributes to mechanosensing and invasive motility. Mol Cancer Res. 12:1416–1429. 2014. View Article : Google Scholar : PubMed/NCBI

17 

Briggs A, Rosenberg L, Buie JD, Rizvi H, Bertagnolli MM and Cho NL: Antitumor effects of hyaluronan inhibition in desmoid tumors. Carcinogenesis. 36:272–279. 2015. View Article : Google Scholar : PubMed/NCBI

18 

Saito T, Dai T and Asano R: The hyaluronan synthesis inhibitor 4-methylumbelliferone exhibits antitumor effects against mesenchymal-like canine mammary tumor cells. Oncol Lett. 5:1068–1074. 2013.PubMed/NCBI

19 

Kim A, Im M, Yim NH and Ma JY: Reduction of metastatic and angiogenic potency of malignant cancer by Eupatorium fortunei via suppression of MMP-9 activity and VEGF production. Sci Rep. 4:69942014. View Article : Google Scholar : PubMed/NCBI

20 

Rauhala L, Hämäläinen L, Salonen P, Bart G, Tammi M, Pasonen-Seppänen S and Tammi R: Low dose ultraviolet B irradiation increases hyaluronan synthesis in epidermal keratinocytes via sequential induction of hyaluronan synthases Has1-3 mediated by p38 and Ca2+/calmodulin-dependent protein kinase II (CaMKII) signaling. J Biol Chem. 288:17999–18012. 2013. View Article : Google Scholar : PubMed/NCBI

21 

Wei K, Kodym R and Jin C: Radioresistant cell strain of human fibrosarcoma cells obtained after long-term exposure to x-rays. Radiat Environ Biophys. 37:133–137. 1998. View Article : Google Scholar : PubMed/NCBI

22 

Speake WJ, Dean RA, Kumar A, Morris TM, Scholefield JH and Watson SA: Radiation induced MMP expression from rectal cancer is short lived but contributes to in vitro invasion. Eur J Surg Oncol. 31:869–874. 2005. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Saga R, Monzen S, Chiba M, Yoshino H, Nakamura T and Hosokawa Y: Anti-tumor and anti-invasion effects of a combination of 4-methylumbelliferone and ionizing radiation in human fibrosarcoma cells. Oncol Lett 13: 410-416, 2017.
APA
Saga, R., Monzen, S., Chiba, M., Yoshino, H., Nakamura, T., & Hosokawa, Y. (2017). Anti-tumor and anti-invasion effects of a combination of 4-methylumbelliferone and ionizing radiation in human fibrosarcoma cells. Oncology Letters, 13, 410-416. https://doi.org/10.3892/ol.2016.5385
MLA
Saga, R., Monzen, S., Chiba, M., Yoshino, H., Nakamura, T., Hosokawa, Y."Anti-tumor and anti-invasion effects of a combination of 4-methylumbelliferone and ionizing radiation in human fibrosarcoma cells". Oncology Letters 13.1 (2017): 410-416.
Chicago
Saga, R., Monzen, S., Chiba, M., Yoshino, H., Nakamura, T., Hosokawa, Y."Anti-tumor and anti-invasion effects of a combination of 4-methylumbelliferone and ionizing radiation in human fibrosarcoma cells". Oncology Letters 13, no. 1 (2017): 410-416. https://doi.org/10.3892/ol.2016.5385
Copy and paste a formatted citation
x
Spandidos Publications style
Saga R, Monzen S, Chiba M, Yoshino H, Nakamura T and Hosokawa Y: Anti-tumor and anti-invasion effects of a combination of 4-methylumbelliferone and ionizing radiation in human fibrosarcoma cells. Oncol Lett 13: 410-416, 2017.
APA
Saga, R., Monzen, S., Chiba, M., Yoshino, H., Nakamura, T., & Hosokawa, Y. (2017). Anti-tumor and anti-invasion effects of a combination of 4-methylumbelliferone and ionizing radiation in human fibrosarcoma cells. Oncology Letters, 13, 410-416. https://doi.org/10.3892/ol.2016.5385
MLA
Saga, R., Monzen, S., Chiba, M., Yoshino, H., Nakamura, T., Hosokawa, Y."Anti-tumor and anti-invasion effects of a combination of 4-methylumbelliferone and ionizing radiation in human fibrosarcoma cells". Oncology Letters 13.1 (2017): 410-416.
Chicago
Saga, R., Monzen, S., Chiba, M., Yoshino, H., Nakamura, T., Hosokawa, Y."Anti-tumor and anti-invasion effects of a combination of 4-methylumbelliferone and ionizing radiation in human fibrosarcoma cells". Oncology Letters 13, no. 1 (2017): 410-416. https://doi.org/10.3892/ol.2016.5385
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team